Bioefficacy of budesonide loaded crosslinked polyeletrolyte microparticles in rat model of induced colitis

References

• Bernkop-Schnürch A, Weithaler A, Albrecht K, Greimel A. (2006). Thiomers: preparation and in vitro evaluation of a mucoadhesive nanoparticulate drug delivery system. Int J Pharm, 317(1), 76–81.
   Google Scholar
• Brogden RN, McTavish D. (1992). Budesonide: an updated review of its pharmacological properties, and therapeutic efficacy in asthma and rhinitis. Drugs, 44(3), 375–407.
   PubMed Web of Science ®Google Scholar
• Chickering DE, Mathiowitz E. (1995). Bioadhesive microspheres: I. A novel electrobalance-based method to study adhesive interactions between individual microspheres and intestinal mucosa. J Control Release, 34, 251–261.
   Web of Science ®Google Scholar
• Chickering DE, Jacob P, Mathiowitz E. (1992). A tensile technique to evaluate the interaction of bioadhesive microspheres with intestinal mucosa. Proc Int Symp Control Release Bioact Mater, 19, 88–89.
   Google Scholar
• Coppi G, Iannuccelli V, Leo E, Bernabei MT, Cameroni R. (2001). Chitosan-alginate microparticles as a protein carrier. Drug Dev Ind Pharm, 27(5), 393–400.
   PubMed Web of Science ®Google Scholar
• Coppi G, Iannuccelli V, Bernabei MT, Cameroni R. (2002). Alginate microparticles for enzyme peroral administration. Int J Pharm, 242(1-2), 263–266.
   PubMedGoogle Scholar
• Davis SS, Hardy JG, Fara JW. (1986). Transit of pharmaceutical dosage forms through the small intestine. Gut, 27, 886–892.
   PubMed Web of Science ®Google Scholar
• Deacon MP, McGurk M, Roberts CJ, Williams PM, Tendler SJB, Davies MC, Davis SS, Hardings SE. (2000). Atomic force microscopy of gastric mucin and chitosan mucoadhesive systems. Biochem J, 348, 557–563.
   PubMed Web of Science ®Google Scholar
• Edsbäcker S, Bengtsson B, Larsson P, Lundin P, Nilsson A, Ulmius J, Wollmer P. (2003). A pharmacoscintigraphic evaluation of oral budesonide given as controlled-release (Entocort) capsule. Aliment Pharmacol Ther, 17, 525–636.
   PubMed Web of Science ®Google Scholar
• Ewe K, Schwartz S, Petersen S, Press AG. (1999). Inflammation does not decrease intraluminal pH in chronic inflammatory bowel disease. Dig Dis Sci, 44, 1434–1439.
   PubMed Web of Science ®Google Scholar
• Fallingborg J, Pedersen P, Jacobsen BA. (1998). Small intestinal transit time and intraluminal pH in ileocecal resected patients with Crohn’s disease. Dig Dis Sci, 43, 702–705.
   PubMed Web of Science ®Google Scholar
• Fedorak RN, Bistritz L. (2005). Targeted delivery, safety, and efficacy of oral enteric-coated formulations of budesonide. Adv Drug Deliver Rev, 57, 303–316.
   PubMed Web of Science ®Google Scholar
• Fiebrig I, Harding SE, Davis SS. (1994). Sedimentation analysis of potential interactions between mucins and a putative bioadhesive polymer. Prog Colloid Polym Sci, 94, 66–73.
   Google Scholar
• Fiebrig I, Harding SE, Rowe AJ, Hyman SC, Davis SS. (1995). Transmission electron microscopy on pig gastric mucin and its interactions with chitosan. Carbohydr Polym, 28, 239–244.
   Web of Science ®Google Scholar
• George M, Abraham TE. (2006). Polyionic hydrocolloids for the intestinal delivery of protein drugs: alginate and chitosan—a review. J Control Rel, 114, 1–14.
   PubMed Web of Science ®Google Scholar
• Glavas Dodov M, Calis S, Simonoska M, Goracinova K. (2006). Formulation and evaluation of 5-FU loaded chitosan/alginate microparticles prepared by spray-drying. 13th International Pharmaceutical Technology Symposium, Turkey.
   Google Scholar
• Glavas Dodov M, Hincal AA, Calis S, Simonoska Crcarevska M, Geskovski N, Goracinova K. (2007). Spray-dried chitosan-Ca-alginate microparticles for colon delivery of 5-FU. Maced Pharm Bull, 53(1,2), 45–46.
   Google Scholar
• Glavas Dodov M, Hincal AA, Calis S, Simonoska Crcarevska M, Geskovski N, Goracinova K. (2008). Chitosan-Ca-Alginate microparticles loaded with HPMCP HP55 coated 5-FU: physical characterization. 6th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical technology, Spain.
   Google Scholar
• Gombotz WR, Wee SF. (1998). Protein release from alginate matrices. Adv Drug Deliver Rev, 31, 267–285.
   PubMed Web of Science ®Google Scholar
• Goracinova K. (2005). Formulation and preparation of spray-dried alginate-Ca microparticles. Patent No. MP/MK/05/01/FF/BE/01/IP.
   Google Scholar
• Goracinova K, Mladenovska K, Glavas Dodov M, Simonoska M. (2005). Optimizing formulation factors in preparation of microparticles by spray-drying process. Abstractbook of 15th International Symposium on Microencapsulation, Italy.
   Google Scholar
• Hardy FH, Davis SS, Khosla R, Robertson CS. (1988). Gastrointestinal transit of small tablets in patients with ulcerative colitis. Int J Pharm, 48, 79–82.
   Web of Science ®Google Scholar
• Hebden JM, Blackshaw PE, Perkins AC, Wilson CG, Spiller RC. (2000). Limited exposure of the healthy distal colon to orally-dosed formulation is further exaggerated in active left-sided ulcerative colitis. Aliment Pharmacol Ther, 14, 155–161.
   PubMed Web of Science ®Google Scholar
• Hejazi R, Amiji M. (2003). Chitosan-based gastrointestinal delivery systems. J Control Rel, 89, 151–165.
   PubMed Web of Science ®Google Scholar
• Huanbutta K, Luangtana-Anan M, Sriamornsaki P, Limmatvapirat S, Puttipipatkhachorn S, Nunthanid J. (2008). Factors affecting preparations of chitosan microcapsules for colonic drug delivery. J. Metals, Mater. Mine, 18(2), 79–83.
   Google Scholar
• Illum L. (1998). Chitosan and its use as a pharmaceutical excipient. Pharm Res, 15, 1326–1331.
   PubMed Web of Science ®Google Scholar
• Lamprecht A, Schafer U, Lehr CM. (2000). Microparticle targeting to the inflamed colonic mucosa for the treatment of inflammatory bowel disease: in vivo results from rat. AAPS Pharm Sci, 2, 1930. [abstract]
   Google Scholar
• Lamprecht A, Schafer U, Lehr CM. (2001a). Size-dependent bioadhesion of micro- and nanoparticulate carriers to the inflamed colonic mucosa. Pharm Res, 18, 788–793.
   PubMed Web of Science ®Google Scholar
• Lamprecht A, Ubrich N, Yamamoto H, Scheafer U, Takeuchi H, Maincent P, Kawashima Y, Lehr CM. (2001b). Biodegradable nanoparticles for targeted drug delivery in treatment of inflammatory bowel disease. J Pharmacol Exp Ther, 299, 775–781.
   PubMed Web of Science ®Google Scholar
• Lamprecht A, Stallmach A, Kawashima Y, Lehr CM. (2002). Carrier systems for the treatment of inflammatory bowel disease. Drugs Future, 27, 961–971.
   Web of Science ®Google Scholar
• Loke WK, Lau SK, Yong LL, Khor E, Sum CK. (2000). Wound dressing with sustained anti-microbial capability. J Biomed Mater Res, 53, 8–17.
   PubMed Web of Science ®Google Scholar
• Lorenzo-Lamosa ML, Remunan-Lopez C, Vila-Jato JL, Alonso MJ. (1998). Design of microencapsulated chitosan microspheres for colonic drug delivery. J Control Release, 52, 109–118.
   PubMed Web of Science ®Google Scholar
• Martinac A, Filipović-Grčić J, Voinovich D, Perissutti B, Franceschinis E. (2005). Development and bioadhesive properties of chitosan-ethylcellulose microspheres for nasal delivery. Int J Pharm, 291(1, 2), 69–77.
   PubMedGoogle Scholar
• McConnell EL, Fadda HM, Basit AW. (2008). Gut instincts: explorations in intestinal physiology and drug delivery. Int J Pharm, 364, 213–226.
   PubMed Web of Science ®Google Scholar
• Meissner Y, Pellequer Y, Lamprecht A. (2006). Nanoparticles in inflammatory bowel disease: particle targeting versus pH-sensitive delivery. Int J Pharm, 316, 138–143.
   PubMed Web of Science ®Google Scholar
• Mi FL, Shyu SS, Wu YB, Lee ST, Shyong JY, Hunag RN. (2001). Fabrication and characterization of a sponge-like asymmetric chitosan membrane as a wound dressing. Biomaterials, 22, 165–173.
   PubMed Web of Science ®Google Scholar
• Mladenovska K, Raicki RS, Janevik EI, Ristoski T, Pavlova MJ, Kavrakovski Z, Dodov MG, Goracinova K. (2007). Colon-specific delivery of 5-aminosalicylic acid from chitosan-Ca-alginate microparticles. Int J Pharm, 342, 124–136.
   PubMed Web of Science ®Google Scholar
• Morris GP, Beck PL, Herridge MS, Depew WT, Szewczuk MY, Wallace JL. (1989). Hapten-induced model of chronic inflammation and ulceration in the rat colon. Gastroenterology, 96, 795–803.
   PubMed Web of Science ®Google Scholar
• Nakase H, Okazaki K, Tabata Y, Uose S, Ohana M, Uchida K, Matsushima Y, Kawanami C, Oshima C, Ikada Y, Chiba T. (2000). Development of an oral drug delivery system targeting immune-regulating cells in experimental inflammatory bowel disease: a new therapeutic strategy. J Pharmacol Exp Ther, 292, 15–21.
   PubMed Web of Science ®Google Scholar
• NATO Science for Peace Project 978023. (2006). Influence of biopolymer interactions on the drug delivery from chitosan-alginate colloidal carrier systems. [Report]
   Google Scholar
• Nilsson M, Edsbacker S, Conradson TB. (1992). Rectal and oral bioavailability of budesonide in man. Hell J Gastroenterol, 5 (Suppl.), 297.
   Google Scholar
• Onishi H, Machida Y. (2008). In vitro and in vivo evaluation of microparticulate drug delivery systems composed of macromolecular prodrugs. Molecules, 13, 2136–2155.
   PubMed Web of Science ®Google Scholar
• Onishi H, Oosegi T, Machida Y. (2008). Efficacy and toxicity of Eudragit-coated chitosan–succinyl-prednisolone conjugate microspheres using rats with 2,4,6-trinitrobenzenesulfonic acid-induced colitis. Int J Pharm, 358, 296–302.
   PubMed Web of Science ®Google Scholar
• Oosegi T, Onishi H, Machida Y. (2008). Gastrointestinal distribution and absorption behavior of eudragit-coated chitosan–prednisolone conjugate microspheres in rats with TNBS-induced colitis. Int J Pharm, 348, 80–88.
   PubMed Web of Science ®Google Scholar
• Press AG, Hauptmann IA, Hauptmann L, Fuchs B, Fuchs M, Ewe K, Ramadori G. (1998). Gastrointestinal pH profiles in patients with inflammatory bowel disease. Aliment Pharmacol Ther, 12, 673–678.
   PubMed Web of Science ®Google Scholar
• Rodriguez M, Antonez JA, Taboada C, Seijo B, Torres D. (2001). Colon-specific delivery of budesonide from microencapsulated cellulosic cores: evaluation of the efficacy against colonic inflammation in rats. J Pharm Pharmacol, 53(9), 1207–1215.
   Web of Science ®Google Scholar
• Rubinstein A. (1995). Approaches and opportunities in colon-specific drug delivery. Crit Rev Ther Drug Carrier Syst, 12, 101–149.
   PubMed Web of Science ®Google Scholar
• Simonoska M, Glavas-Dodov M, Dimitrovska A, Goracinova K. (2006). Microparticle design for colon delivery of budesonide. 13th International Pharmaceutical Technology Symposium, Turkey.
   Google Scholar
• Simonoska M, Glavas-Dodov M, Goracinova K. (2007). Enteric coated chitosan-Ca-alginate microparticles for colon drug delivery. Maced Pharm Bull, 53(1,2), 55–56.
   Google Scholar
• Simonoska Crcarevska M, Goracinova K, Glavas Dodov M, Steffansen B. (2007). Uptake studies of chitosan-Ca-alginate microparticles loaded with 5-FU in human intestinal cell lines. Maced Pharm Bull, 53(1,2), 24.
   Google Scholar
• Simonoska Crcarevska M, Glavas Dodov M, Goracinova K. (2008). Chitosan coated Ca-alginate microparticles loaded with budesonide for delivery to the inflamed colonic mucosa. Eur J Pharm Biopharm, 68(3), 565–578.
   PubMed Web of Science ®Google Scholar
• Tabata Y, Ikada Y. (1988). Effect of the size and surface charge of polymer microspheres on their phagocytosis by macrophage. Biomaterials, 9, 356–362.
   PubMed Web of Science ®Google Scholar
• Tabata Y, Ikada Y. (1990). Phagocytosis of polymer microspheres by macrophages. Adv Polym Sci, 94, 107–141.
   Web of Science ®Google Scholar
• Tabata Y, Inoue Y, Ikada Y. (1996). Size effect on systemic and mucosal immune responses induced by oral administration of biodegradable microspheres. Vaccine, 14, 1677–1685.
   PubMed Web of Science ®Google Scholar
• Tirosh B, Rubinstein A. (1998). Migration of adhesive and nonadhesive particles in the rat intestine under altered mucus secretion conditions. J Pharm Sci, 87, 453–456.
   PubMed Web of Science ®Google Scholar
• Tozaki H, Fujita T, Komoike J, Kim SI, Terashima H, Muranishi S, Okabe S, Yamamoto A. (1999). Colon-specific delivery of budesonide with azopolymer-coated pellets: therapeutic effects of budesonide with a novel dosage form against 2,4,6,-trinitrobenzensulphonic acid-induced colitis in rats. J Pharm Pharmacol, 51, 257–261.
   PubMed Web of Science ®Google Scholar
• Tozaki H, Odoriba T, Okada N, Fujita T, Terabe A, Suzuki T, Okabe S, Muranishi S, Yamamoto A. (2002). Chitosan capsules for colon-specific drug delivery: enhanced localization of 5-aminosalicylic acid in the large intestine accelerates healing of TNBS-induced colitis in rats. J Control Release, 82(1), 51–61.
   PubMed Web of Science ®Google Scholar
• Van Der Lubben IM, Konings FA, Borchard G, Verhoef JC, Junginger HE. (2001). In vivo uptake of chitosan microparticles by murine Peyer’s patches: visualization studies using confocal laser scanning microscopy and immunohistochemistry. J Drug Target, 9, 39–47.
   PubMed Web of Science ®Google Scholar
• Varum FJO, McConnell EL, Sousa JJS, Veiga F, Basit AW. (2008). Mucoadhesion and the gastrointestinal tract. Crit Rev Ther Drug Carrier Syst, 25(3), 207–258.
   PubMed Web of Science ®Google Scholar
• Vassallo M, Camilleri M, Phillips SF, Brown ML, Chapman NJ, Thomforde GM. (1992). Transit through the proximal colon influences stool weight in the irritable bowel syndrome. Gastroenterology, 102, 102–108.
   PubMed Web of Science ®Google Scholar
• Watts PJ, Barrow L, Steed KP, Wilson CG, Spiller RC, Melia CD, Davies MC. (1992). The transit rate of different-sized model dosage forms through the human colon and the effects of a lactulose-induced catharsis. Int J Pharm, 87, 215–221.
   Web of Science ®Google Scholar
• Wittaya-areekul S, Kruenate J, Prahsarn C. (2006). Preparation and in vitro evaluation of mucoadhesive properties of alginate/chitosan microparticles containing prednisolone. Int J Pharm, 312, 113–118.
   PubMed Web of Science ®Google Scholar
• Yamada T, Marshall S, Specian RD, Grisham MB. (1992). A comparative analysis of two models of colitis in rats. Gastroenterology, 102, 1524–1534.
   PubMed Web of Science ®Google Scholar
• Yan X-L, Khor E, Lim L-Y. (2001).Chitosan-alginate films prepared with chitosans of different molecular weights. J Biomed Mater Res, 58(4), 358–365.
   PubMed Web of Science ®Google Scholar
• Yue G, Sun FF, Dunn C, Yin K, Wong PYK. (1996). The 21-aminosteroid tirilazad mesylate can ameliorate inflammatory bowel disease in rats. J Pharmacol Exp Ther, 276, 265–270.
   PubMed Web of Science ®Google Scholar